Most drugs never reach FDA approval. Bayer's Sunharbo, first of a new class, just did, to reduce repeat strokes. The bit I'd check in the trial data is bleeding. The mechanism is "thought to" stop bad clots without raising that risk, and that's the whole point of the class.
SSTAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and moreSTAT ·